Stacks Image 5


Acute toxicity testing requires test materials to be given to animals for a predefined short period of time in the form of a single exposure. The test material can be managed in different ways to determine its ability to induce toxicity and oral, dermal, or inhalation exposures.




The application areas include pharmaceuticals, medical devices, cosmetics, industrial and consumer-oriented chemicals, and biocides, including different casewise mixtures and related-use areas like safe packaging, clothing for human use, and other concerns.


Acute Toxicity Test Overview

Acute toxicity is caused by the adverse effects of a substance that result from a single or multiple exposures in a short time, typically not more than 24 hours.

Acute Toxicity Testing requires the choice of the appropriate method to recognize symptoms and life-threatening effects as well as differentiation from chronic toxicity. The methods use preferably non-animal but also animal-based species.

Acute toxicity describes the adverse effects that result either from a single or from multiple substance exposures. To be called acute toxicity, side effects should occur within 14 days of administration of the substance. Acute toxicity is different from chronic toxicity. Harmful substance effects cause chronic toxicity during repeated exposure over a long time, sometimes over months or even years.

Acute toxicity studies usually include three routes: oral, dermal, and inhalation. Acute toxicity tests in animals, such as rats, mice, rabbits, or guinea pigs, use mortality as the primary observational endpoint to derive the LD50 (Lethal Dose 50) value, which is the common dose-response descriptor for acute toxicity. The dose is statistically derived; 50% of the individuals are expected to die.

Acute Toxicity Testing Service


Our optional offering includes the determination of the starting dose for acute oral systemic toxicity tests in rodents, according to OECD GD 129. In vitro cytotoxicity assays allow the estimate of a starting LD50 dose to reduce the number of animals by up to 28% for acute oral toxicity testing and as much as 50% for non-classified substances.

Before testing, the determination of the starting dose is determined and based on cytotoxicity testing compliant with OECD GD 129. Eight different test item concentrations are applied.

We provide three different assays:

1. BALB 3T3 / Neutral Red uptake assay (NRU) to predict acute chemicals toxicity.

The assay system is using Mouse BALB / 3T3 fibroblasts. It is based on the ability of viable cells to incorporate and bind the cationic dye Neutral Red. Neutral Red diffuses through the plasma membrane and accumulates in lysosomes. Toxic compounds can alter the cell surface or the lysosomal membrane. Such adverse changes may cause cell death and/or cell growth inhibition, leading to a decreased amount of Neutral Red retained by the cell.

2. Human BJ /Neutral red Uptake Assay to predict acute chemicals toxicity, intra-laboratory validation in FICAM.

This assay is similar to the BALB 3T3 / NRU uptake assay, using human BJ fibroblasts instead of the mouse 3T3 fibroblasts.

3.Human THP-1 Macrophage / WST-1 Assay for predicting acute chemicals toxicity, intra-laboratory validation in FICAM.

As an alternative, the human THP-1 Macrophage WST-1 assay can also be used to predict the acute toxicity of chemicals. It is a viability/proliferation assay based on the conversion of the tetrazolium salt WST-1 into a colored dye formazan by mitochondrial enzymes.


Compare in Portrait Screen Mode

Overview
Acute toxicity is caused by the adverse effects of a substance that result from a single or multiple exposures in a short time, typically not more than 24 hours.

Acute Toxicity Testing requires the choice of the appropriate method to recognize symptoms and life-threatening effects as well as differentiation from chronic toxicity. The methods use preferably non-animal but also animal-based species.

Acute toxicity describes the adverse effects that result either from a single or from multiple substance exposures. To be called acute toxicity, side effects should occur within 14 days of administration of the substance. Acute toxicity is different from chronic toxicity. Harmful substance effects cause chronic toxicity during repeated exposure over a long time, sometimes over months or even years.

Acute toxicity studies usually include three routes: oral, dermal, and inhalation. Acute toxicity tests in animals, such as rats, mice, rabbits, or guinea pigs, use mortality as the primary observational endpoint to derive the LD50 (Lethal Dose 50) value, which is the common dose-response descriptor for acute toxicity. The dose is statistically derived; 50% of the individuals are expected to die.
Acute Toxicity Testing Service

Our optional offering includes the determination of the starting dose for acute oral systemic toxicity tests in rodents, according to OECD GD 129. In vitro cytotoxicity assays allow the estimate of a starting LD50 dose to reduce the number of animals by up to 28% for acute oral toxicity testing and as much as 50% for non-classified substances.

Before testing, the determination of the starting dose is determined and based on cytotoxicity testing compliant with OECD GD 129. Eight different test item concentrations are applied.
We provide three different assays:

1. BALB 3T3 / Neutral Red uptake assay (NRU) to predict acute chemicals toxicity.

The assay system is using Mouse BALB / 3T3 fibroblasts. It is based on the ability of viable cells to incorporate and bind the cationic dye Neutral Red. Neutral Red diffuses through the plasma membrane and accumulates in lysosomes. Toxic compounds can alter the cell surface or the lysosomal membrane. Such adverse changes may cause cell death and/or cell growth inhibition, leading to a decreased amount of Neutral Red retained by the cell.
2. Human BJ /Neutral red Uptake Assay to predict acute chemicals toxicity, intra-laboratory validation in FHAIVE.
This assay is similar to the BALB 3T3 / NRU uptake assay, using human BJ fibroblasts instead of the mouse 3T3 fibroblasts.

3.Human THP-1 Macrophage / WST-1 Assay for predicting acute chemicals toxicity, intra-laboratory validation in FHAIVE.
As an alternative, the human THP-1 Macrophage WST-1 assay can also be used to predict the acute toxicity of chemicals. It is a viability/proliferation assay based on the conversion of the tetrazolium salt WST-1 into a colored dye formazan by mitochondrial enzymes.